Compare Organon & Co. Common Stock (OGN) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Global X Defense Tech ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Global X Defense Tech ETF trades at $59.78 (market cap $6.34B). The key difference: Global X Defense Tech ETF is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Global X Defense Tech ETF for 45 Days on average.
| OGN | SHLD | |
|---|---|---|
Market Cap | $3.62B | $6.34B |
Volume | 2,892,999 | 1,202,620 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $78.02 |
52-Week Low | $5.70 | $58.20 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF focuses on defense technology and cybersecurity with global diversification beyond U.S. names. Recent institutional buying includes Focus Financial Network increasing its stake by 55.4% in Q2 2026 (SEC filing, August 2026) and Balefire LLC's new $1.12 million position.
Geopolitical tensions and rising global defense budgets support long-term growth potential, though the ETF faces competition from broader aerospace funds and sensitivity to defense policy changes. The current technical weakness near support at $58-59 presents a potential entry point for investors bullish on defense tech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
